Petros Family Wealth LLC Makes New $271,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Petros Family Wealth LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,931 shares of the biopharmaceutical company’s stock, valued at approximately $271,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last quarter. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Up 2.2 %

Shares of Gilead Sciences stock opened at $103.63 on Friday. The firm has a market capitalization of $129.04 billion, a PE ratio of 280.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm’s 50 day moving average is $108.34 and its 200 day moving average is $96.79. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

Wall Street Analyst Weigh In

Several research firms have commented on GILD. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Wells Fargo & Company boosted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.